ReviewJournal of the American College of Cardiology2024
Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.
Review in Journal of the American College of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Knowledge domain and evolutionary trends of P2Y receptors in cardiovascular diseases: a bibliometric and altmetric analysis.Frontiers in pharmacology · 2025Pooled it
- Antiplatelet Therapy in Patients Receiving Percutaneous Coronary Intervention for Bifurcation Lesions.Korean circulation journal · 2026Review
- Modern Era in Personalized Medicine of Dual Antiplatelet Therapy After Myocardial Revascularization.Journal of clinical medicine · 2026Review
- 2025 Acute Coronary Syndrome Guideline: Missing the Boat onJournal of the American Heart Association · 2026Review
- Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature.Clinical and translational science · 2026Review
- Clinical pharmacology of antiplatelet drugs: implications for personalized therapy.European journal of clinical pharmacology · 2026Review
- Clinical Application of Pharmacogenomics in Stroke Management: Current Evidence and Future Directions.Journal of stroke · 2026Review
- Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin.Frontiers in pharmacology · 2026Article
- Development and validation of a clinical-pharmacogenomic prediction model for clopidogrel-related high on-treatment platelet reactivity in patients with coronary artery disease.Frontiers in cardiovascular medicine · 2026Article
- Pharmacogenetics in pediatric cardiology.Frontiers in pediatrics · 2026Article
- Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes.Annals of human genetics · 2025Review
- Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.European heart journal. Cardiovascular pharmacotherapy · 2025Observational
- Discovery of ancestry-specific variants associated with clopidogrel response among Caribbean Hispanics.NPJ genomic medicine · 2025Article
- Radial Access and Fondaparinux: A Synergistic Interaction.Arquivos brasileiros de cardiologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring antiplatelet treatment based on genetic variants can potentially result in optimized dosing or a change in drug selection. Most evidence supports guiding therapy based on the CYP2C19 allelic variants in patients with an indication for dual antiplatelet therapy. In ticagrelor-treated or prasugrel-treated patients, a genotype-guided de-escalation strategy can reduce bleeding risk, whereas in patients treated with clopidogrel, an escalation strategy may prevent ischemic events. Although the clinical results are promising, few hospitals have implemented these strategies. New results, technological advancements, and growing experience may potentially overcome current barriers for implementation in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.